News Payday for AbbVie as Humira biosimilar delayed for five year... Deal with Amgen signals exclusivity until 2023 for mega-blockbuster
News FDA rejects J&J's sirukumab RA drug The FDA has rejected Johnson & Johnson’s next-generation rheumatoid arthritis drug, sirukumab, calling for more clinical data to evaluate its safety.
News Sanofi showcases eczema data ahead of EU decision Dupixent predicted to be blockbuster for Sanofi
News Janssen/AbbVie drug approved in graft-versus-host disease First use for Imbruvica outside blood cancer.
News FDA advisers reject J&J rheumatoid arthritis drug Expert panel concerned about safety of sirukumab.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
